Zoetis Inc. (ZTS)

Zoetis Inc. is trading at $73.45, up 0.66% on the session. The 50 day average sits at $76.43 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 44.9, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $73.55 with resistance near $77.99, so that band frames the current range. Average daily movement is roughly $2.98, or about 4.1% of the share price, which is what any stop placement has to allow for. The overall health score of 40 out of 100 combines a trend score of 32, momentum of 29 and a risk score of 68.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.